Инфекция Clos tri dium diffi cile и ее влияние на течение воспалительных заболеваний кишечника
https://doi.org/10.30629/0023-2149-2022-100-7-8-346-356
Аннотация
Воспалительные заболевания кишечника (ВЗК) — распространенные аутоиммунные заболевания с желудочно-кишечными и внекишечными проявлениями и осложнениями. Наиболее частым инфекционным осложнением, связанным с ВЗК, является инфекция Clostridium diffi cile (C. diffi cile). Активное ВЗК предрасполагает к развитию инфекции C. diffi cile из-за изменений в микробиоме кишечника. C. diffi cile представляет собой токсин-продуцирующую бактерию, которая приводит к ухудшению течения ВЗК, увеличивая риск неэффективности лечения основного заболевания, госпитализации и хирургического вмешательства.
Об авторах
Д. С. Пургина
«Лахта Клиника»
Россия
Россия
Пургина Даниэла Сергеевна (Purgina Daniela S.) — врач-гастроэнтеролог, диетолог
197183, Санкт-Петербург
Л. В. Лялина
ФБУН «Санкт-Петербургский научно-исследовательский институт эпидемиологии и микробиологии им. Пастера» Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека; ФГБОУ ВО «Северо-Западный государственный медицинский университет им. И.И. Мечникова» Минздрава России
Россия
Россия
Лялина Людмила Владимировна (Lyalina Lyudmila V.) — д-р мед.
наук, профессор, заведующая лабораторией эпидемиологии инфекционных и неинфекционных заболеваний
197101, Санкт-Петербург; 191015, Санкт-Петербург
В. В. Рассохин
ФБУН «Санкт-Петербургский научно-исследовательский институт эпидемиологии и микробиологии им. Пастера» Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека; ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова» Минздрава России
Россия
Россия
Рассохин Вадим Владимирович (Rassokhin Vadim V.) — д-р мед. наук, профессор кафедры социально значимых инфекций ; ведущий научный сотрудник; заведующий лабораторией хронических вирусных инфекций отдела экологической физиологии
197101, Санкт-Петербург; 197022, Санкт-Петербург
Список литературы
1. Sethi A.K., Al-Nassir W.N., Nerandzic M.M., Bobulsky G.S., Donskey C.J. Persistence of skin contamination and environmental shedding of Clostridium diffi cile during and after treatment of C. diffi cile infection. Infect. Control Hosp. Epidemiol. 2010;31(1):21– 7. DOI: 10.1086/649016
2. Knight D.R., Riley T.V. Genomic Delineation of Zoonotic Origins of Clostridium diffi cile. Front Public Health. 2019;7:164. DOI: 10.3389/fpubh.2019.00164
3. Czepiel J., Dróżdż M., Pituch H., Kuijper EJ., Perucki W., Mielimonka A., Goldman S., Wultańska D., Garlicki A., Biesiada G. Clostridium diffi cile infection: review. Eur. J. Clin. Microbiol. Infect. Dis. 2019;38(7):1211–1221. DOI: 10.1007/s10096-019-03539-6
4. Lim S.C., Knight D.R., Riley T.V. Clostridium diffi cile and One Health. Clin. Microbiol. Infect. 2020;26(7):857–863. DOI: 10.1016/j.cmi.2019.10.023
5. Regnault H., Bourrier A., Lalande V., Nion-Larmurier I., Sokol H., Seksik P., Barbut F., Cosnes J., Beaugerie L. Prevalence and risk factors of Clostridium diffi cile infection in patients hospitalized for fl are of infl ammatory bowel disease: a retrospective assessment. Dig. Liver Dis. 2014;46(12):1086–92. DOI: 10.1016/j.dld.2014.09.003
6. Leffl er D.A., Lamont J.T. Clostridium diffi cile infection. N. Engl. J. Med. 2015;372(16):1539–48. DOI: 10.1056/NEJMra1403772
7. Hensgens M.P., Goorhuis A., Dekkers O.M., Kuijper E.J. Time interval of increased risk for Clostridium diffi cile infection after exposure to antibiotics. J. Antimicrob. Chemother. 2012;67(3):742–8. DOI: 10.1093/jac/dkr508
8. Khanna S., Pardi D.S., Aronson S.L., Kammer P.P., Orenstein R., St Sauver J.L., Harmsen W.S., Zinsmeister A.R. The epidemiology of community-acquired Clostridium diffi cile infection: a populationbased study. Am. J. Gastroenterol. 2012;107(1):89–95. DOI: 10.1038/ajg.2011.398
9. Novack L., Kogan S., Gimpelevich L., Howell M., Borer A., Kelly C.P., Leffl er D.A., Novack V. Acid suppression therapy does not predispose to Clostridium diffi cile infection: the case of the potential bias. PLoS One. 2014;9(10):e110790. DOI: 10.1371/journal.pone.0110790
10. Burke K.E., Lamont J.T. Clostridium diffi cile infection: a worldwide disease. Gut Liver. 2014;8(1):1–6. DOI: 10.5009/gnl.2014.8.1.1
11. Kochan T.J., Somers M.J., Kaiser A.M., Shoshiev M.S., Hagan A.K., Hastie J.L., Giordano N.P., Smith A.D., Schubert A.M., Carlson P.E. Jr., Hanna P.C. Intestinal calcium and bile salts facilitate germination of Clostridium diffi cile spores. PLoS Pathog. 2017;13(7):e1006443. DOI: 10.1371/journal.ppat.1006443
12. Austin M., Mellow M., Tierney W.M. Fecal microbiota transplantation in the treatment of Clostridium diffi cile infections. Am. J. Med. 2014;127(6):479–83. DOI: 10.1016/j.amjmed.2014.02.017
13. Antharam V.C., Li E.C., Ishmael A., Sharma A., Mai V., Rand K.H., Wang G.P. Intestinal dysbiosis and depletion of butyrogenic bacteria in Clostridium diffi cile infection and nosocomial diarrhea. J. Clin. Microbiol. 2013;51(9):2884–92. DOI: 10.1128/JCM.00845-13
14. Vincent C., Stephens D.A., Loo V.G., Edens T.J., Behr M.A., Dewar K., Manges A.R. Reductions in intestinal Clostridiales precede the development of nosocomial Clostridium diffi cile infection. Microbiome. 2013;1(1):18. DOI: 10.1186/2049-2618-1-18
15. Gu S., Chen Y., Zhang X., Lu H., Lv T., Shen P., Lv L., Zheng B., Jiang X., Li L. Identifi cation of key taxa that favor intestinal colonization of Clostridium diffi cile in an adult Chinese population. Microbes Infect. 2016;18(1):30–8. DOI: 10.1016/j.micinf.2015.09.008
16. Zhang L., Dong D., Jiang C., Li Z., Wang X., Peng Y. Insight into alteration of gut microbiota in Clostridium diffi cile infection and asymptomatic C. diffi cile colonization. Anaerobe. 2015;34:1–7. DOI: 10.1016/j.anaerobe.2015.03.008
17. Francis M.B., Allen C.A., Shrestha R., Sorg J.A. Bile acid recognition by the Clostridium diffi cile germinant receptor, CspC, is important for establishing infection. PLoS Pathog. 2013;9(5):e1003356. DOI: 10.1371/journal.ppat.1003356
18. Buffi e C.G., Bucci V., Stein R.R., McKenney P.T., Ling L., Gobourne A., No D., Liu H., Kinnebrew M., Viale A., Littmann E., van den Brink M.R., Jenq R.R., Taur Y., Sander C., Cross J.R., Toussaint N.C., Xavier J.B., Pamer E.G. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium diffi cile. Nature. 2015;517(7533):205–8. DOI: 10.1038/nature13828
19. Androga G.O., Hart J., Foster N.F., Charles A., Forbes D., Riley T.V. Infection with Toxin A-Negative, Toxin B-Negative, Binary ToxinPositive Clostridium diffi cile in a Young Patient with Ulcerative Colitis. J. Clin. Microbiol. 2015;53(11):3702–4. DOI: 10.1128/JCM.01810-15
20. Brito G.A., Sullivan G.W., Ciesla W.P. Jr., Carper H.T., Mandell G.L., Guerrant R.L. Clostridium diffi cile toxin A alters in vitro-adherent neutrophil morphology and function. J. Infect. Dis. 2002;185(9):1297–306. DOI: 10.1086/340236
21. Péchiné S., Collignon A. Immune responses induced by Clostridium diffi cile. Anaerobe. 2016;41:68–78. DOI: 10.1016/j.anaerobe.2016.04.014
22. Hughes M., Qazi T., Berg A., Weinberg J., Chen X., Kelly C.P., Farraye F.A. Host immune response to clostridium diffi cile infection in infl ammatory bowel disease patients. Infl amm. Bowel Dis. 2016;22(4):853–61. DOI: 10.1097/MIB.0000000000000696
23. Li Y., Qian J., Queener E., Shen B. Risk factors and outcome of PCR-detected Clostridium diffi cile infection in ileal pouch patients. Infl amm. Bowel Dis. 2013;19(2):397–403. DOI: 10.1097/MIB.0b013e318280fcb9
24. D’Aoust J., Battat R., Bessissow T. Management of infl ammatory bowel disease with Clostridium diffi cile infection. World J. Gastroenterol. 2017;23(27):4986–5003. DOI: 10.3748/wjg.v23.i27.4986
25. Nitzan O., Elias M., Chazan B., Raz R., Saliba W. Clostridium diffi cile and infl ammatory bowel disease: role in pathogenesis and implications in treatment. World J. Gastroenterol. 2013;19(43):7577– 85. DOI: 10.3748/wjg.v19.i43.7577
26. Rao K., Higgins P.D. Epidemiology, diagnosis, and management of clostridium diffi cile infection in patients with infl ammatory bowel disease. Infl amm. Bowel Dis. 2016;22(7):1744–54. DOI: 10.1097/ MIB.0000000000000793
27. Ross C.L., Spinler J.K., Savidge T.C. Structural and functional changes within the gut microbiota and susceptibility to Clostridium diffi cile infection. Anaerobe. 2016;41:37–43. DOI: 10.1016/j.anaerobe.2016.05.006
28. Freeman H.J. Recent developments on the role of Clostridium diffi cile in infl ammatory bowel disease. World J. Gastroenterol. 2008;14(18):2794–6. DOI: 10.3748/wjg.14.2794
29. Trifan A., Stanciu C., Stoica O., Girleanu I., Cojocariu C. Impact of Clostridium diffi cile infection on infl ammatory bowel disease outcome: a review. World J. Gastroenterol. 2014;20(33):11736–42. DOI: 10.3748/wjg.v20.i33.11736
30. Surawicz C.M., Brandt L.J., Binion D.G., Ananthakrishnan A.N., Curry S.R., Gilligan P.H., McFarland L.V., Mellow M., Zuckerbraun B.S. Guidelines for diagnosis, treatment, and prevention of Clostridium diffi cile infections. Am. J. Gastroenterol. 2013;108(4):478–98; quiz 499. DOI: 10.1038/ajg.2013.4
31. Issa M., Vijayapal A., Graham M.B., Beaulieu D.B., Otterson M.F., Lundeen S., Skaros S., Weber L.R., Komorowski R.A., Knox J.F., Emmons J., Bajaj J.S., Binion D.G. Impact of Clostridium diffi - cile on infl ammatory bowel disease. Clin. Gastroenterol. Hepatol. 2007;5(3):345–51. DOI: 10.1016/j.cgh.2006.12.028
32. Meyer A.M., Ramzan N.N., Loftus E.V. Jr., Heigh R.I., Leighton J.A. The diagnostic yield of stool pathogen studies during relapses of infl ammatory bowel disease. J. Clin. Gastroenterol. 2004;38(9):772–5. DOI: 10.1097/01.mcg.0000139057.05297.d6
33. Clayton E.M., Rea M.C., Shanahan F., Quigley E.M., Kiely B., Hill C., Ross R.P. The vexed relationship between Clostridium diffi - cile and infl ammatory bowel disease: an assessment of carriage in an outpatient setting among patients in remission. Am. J. Gastroenterol. 2009;104(5):1162–9. DOI: 10.1038/ajg.2009.4
34. Nguyen G.C., Kaplan G.G., Harris M.L., Brant S.R. A national survey of the prevalence and impact of Clostridium diffi cile infection among hospitalized infl ammatory bowel disease patients. Am. J. Gastroenterol. 2008;103(6):1443–50. DOI: 10.1111/j.1572-0241.2007.01780.x
35. Gianotti R.J., Moss A.C. The Use and Effi cacy of Fecal Microbiota Transplantation for Refractory Clostridium diffi cile in Patients with Infl ammatory Bowel Disease. Infl amm Bowel Dis. 2016;22(11):2704– 2710. DOI: 10.1097/MIB.0000000000000950
36. Jabbar U., Leischner J., Kasper D., Gerber R., Sambol S.P., Parada .P., Johnson S., Gerding D.N. Eff ectiveness of alcohol-based hand rubs for removal of Clostridium diffi cile spores from hands. Infect. Control Hosp. Epidemiol. 2010;31(6):565–70. DOI: 10.1086/652772
37. Cornely O.A., Miller M.A., Louie T.J., Crook D.W., Gorbach S.L. Treatment of fi rst recurrence of Clostridium diffi cile infection: fi daxomicin versus vancomycin. Clin. Infect. Dis. 2012;55(2):S154– 61. DOI: 10.1093/cid/cis462
38. Bien J., Palagani V., Bozko P. The intestinal microbiota dysbiosis and Clostridium diffi cile infection: is there a relationship with infl ammatory bowel disease? Therap. Adv. Gastroenterol. 2013;6(1):53– 68. DOI: 10.1177/1756283X12454590
39. Navaneethan U., Venkatesh P.G., Shen B. Clostridium diffi cile infection and infl ammatory bowel disease: understanding the evolving relationship. World J. Gastroenterol. 2010;16(39):4892– 904. DOI: 10.3748/wjg.v16.i39.4892
40. Hughes M., Qazi T., Berg A., Weinberg J., Chen X., Kelly C.P., Farraye F.A. Host Immune Response to Clostridium diffi cile Infection in Infl ammatory Bowel Disease Patients. Infl amm. Bowel Dis. 2016;22(4):853–61. DOI: 10.1097/MIB.0000000000000696
41. D’Aoust J., Battat R., Bessissow T. Management of infl ammatory bowel disease with Clostridium diffi cile infection. World J. Gastroenterol. 2017;23(27):4986–5003. DOI: 10.3748/wjg.v23.i27.4986
42. McDonald L.C., Gerding D.N., Johnson S., Bakken J.S., Carroll K.C., Coffi n S.E., Dubberke E.R., Garey K.W., Gould C.V., Kelly C., Loo V., Shaklee Sammons J., Sandora T.J., Wilcox M.H. Clini cal Practice Guidelines for Clostridium diffi cile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin. Infect. Dis. 2018;66(7):e1–e48. DOI: 10.1093/cid/cix1085
43. McFarland L.V. Antibiotic-associated diarrhea: epidemiology, trends and treatment. Future Microbiol. 2008;3(5):563–78. DOI: 10.2217/17460913.3.5.563
44. Jose S., Madan R. Neutrophil-mediated infl ammation in the pathogenesis of Clostridium diffi cile infections. Anaerobe. 2016;41:85– 90. DOI: 10.1016/j.anaerobe.2016.04.001
45. Czepiel J., Dróżdż M., Pituch H., Kuijper E.J., Perucki W., Mielimonka A., Goldman S., Wultańska D., Garlicki A., Biesiada G. Clostridium diffi cile infection: review. Eur. J. Clin. Microbiol. Infect. Dis. 2019;38(7):1211–1221. DOI: 10.1007/s10096-019-03539-6
46. Wilcox M.H., Fawley W.N., Wigglesworth N., Parnell P., Verity P., Freeman J. Comparison of the eff ect of detergent versus hypochlorite cleaning on environmental contamination and incidence of Clostridium diffi cile infection. J. Hosp. Infect. 2003;54(2):109–14. DOI: 10.1016/s0195-6701(02)00400-0
47. Bartlett J.G. Detection of Clostridium diffi cile infection. Infect. Control Hosp. Epidemiol. 2010;31(1):S35–7. DOI: 10.1086/655999
48. Simor A.E. Diagnosis, management, and prevention of Clostridium diffi cile infection in long-term care facilities: a review. J. Am. Geriatr. Soc. 2010;58(8):1556–64. DOI: 10.1111/j.1532-5415.2010.02958.x
49. Лобзин Ю.В., Захаренко С.М., Иванов Г.А. Современные пред ставления об инфекции Clostridium diffi cile. Клиническая микробиология и антимикробная химиотерапия. 2002;3(4):200– 232.
50. Ивашкин В.Т., Ющук Н.Д, Маев И.В., Лапина Т.Л., Полуэктова Е.А., Шифрин О.С., Тертычный А.С., Трухманов А.С., Шептулин А.А., Баранская Е.К., Ляшенко О.С., Ивашкин К.В. Рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению Clostridium diffi cile-ассоциированной болезни. Российский журнал гастроэнтерологии, гепатологии, колопроктологии 2016;26(5).
51. Crobach M.J., Planche T., Eckert C., Barbut F., Terveer E.M., Dekkers O.M., Wilcox M.H., Kuijper E.J. European Society of Clinical Microbiology and Infectious Diseases: update of the diagnostic guidance document for Clostridium diffi cile infection. Clin. Microbiol. Infect. 2016;22(4):63–81. DOI: 10.1016/j.cmi.2016.03.010
52. Ananthakrishnan A.N., Binion D.G. Impact of Clostridium diffi cile on infl ammatory bowel disease. Expert Rev. Gastroenterol. Hepatol. 2010;4(5):589–600. DOI: 10.1586/egh.10.55
53. Farooq P.D., Urrunaga N.H., Tang D.M, von Rosenvinge E.C. Pseudomembranous colitis. Dis. Mon. 2015;61(5):181–206. DOI: 10.1016/j.disamonth.2015.01.006
54. Vaishnavi C. Clinical spectrum & pathogenesis of Clostridium diffi - cile associated diseases. Indian J. Med. Res. 2010;131:487–99.
55. Bitton A., Buie D., Enns R., Feagan B.G., Jones J.L., Marshall J.K., Whittaker S., Griffi ths A.M., Panaccione R. Canadian Association of Gastroenterology Severe Ulcerative Colitis Consensus Group. Treatment of hospitalized adult patients with severe ulcerative colitis: Toronto consensus statements. Am. J. Gastroenterol. 2012;107(2):179– 94; author reply 195. DOI: 10.1038/ajg.2011.386
56. McFarland L.V., Elmer G.W., Surawicz C.M. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium diffi cile disease. Am. J. Gastroenterol. 2002;97(7):1769–75. DOI: 10.1111/j.1572-0241.2002.05839.x
57. Horton H.A., Dezfoli S., Berel D., Hirsch J., Ippoliti A., McGovern D., Kaur M., Shih D., Dubinsky M., Targan S.R., Fleshner P., Vasiliauskas E.A., Grein J., Murthy R., Melmed G.Y. Antibiotics for treatment of clostridium diffi cile infection in hospitalized patients with infl ammatory bowel disease. Antimicrob. Agents Chemother. 2014;58(9):5054–9. DOI: 10.1128/AAC.02606-13
58. Beniwal-Patel P., Stein D.J., Munoz-Price L.S. The Juncture Between Clostridioides diffi cile Infection and Infl ammatory Bowel Diseases. Clin. Infect. Dis. 2019;69(2):366–372. DOI: 10.1093/cid/ciz061
59. Surawicz C.M., Brandt L.J., Binion D.G., Ananthakrishnan A.N., Curry S.R., Gilligan P.H., McFarland L.V., Mellow M., Zuckerbraun B.S. Guidelines for diagnosis, treatment, and prevention of Clostridium diffi cile infections. Am. J. Gastroenterol. 2013;108(4):478–98; quiz 499. DOI: 10.1038/ajg.2013.4
60. Loo V.G., Poirier L., Miller M.A., Oughton M., Libman M.D., Michaud S., Bourgault A.M., Nguyen T., Frenette C., Kelly M., Vibien A., Brassard P., Fenn S., Dewar K., Hudson T.J., Horn R., René P., Monczak Y., Dascal A. A predominantly clonal multi-institutional outbreak of Clostridium diffi cile-associated diarrhea with high morbidity and mortality. N. Engl. J. Med. 2005;353(23):2442–9. DOI: 10.1056/NEJMoa051639
61. [Electronic resource]. URL: https://www.sciencephoto.com/media/11348/view
62. Chung H.S., Park J.S., Shin B.M. Laboratory Diagnostic Methods for Clostridioides diffi cile Infection: the First Systematic Review and Meta-analysis in Korea. Ann. Lab. Med. 2021;41(2):171–180. DOI:10.3343/alm.2021.41.2.171
63. Bartlett J.G. Bezlotoxumab — A New Agent for Clostridium diffi cile Infection. N. Engl. J. Med. 2017;376(4):381–382. DOI: 10.1056/NEJMe1614726
64. Wilcox M.H., Gerding D.N., Poxton I.R., Kelly C., Nathan R., Birch T., Cornely O.A., Rahav G., Bouza E., Lee C., Jenkin G., Jensen W., Kim Y.S., Yoshida J., Gabryelski L., Pedley A., Eves K., Tipping R., Guris D., Kartsonis N., Dorr M.B. MODIFY I and MODIFY II Investigators. Bezlotoxumab for Prevention of Recurrent Clostridium diffi cile Infection. N. Engl. J. Med. 2017;376(4):305– 317. DOI: 10.1056/NEJMoa1602615
65. Ooijevaar R.E., van Beurden Y.H., Terveer E.M., Goorhuis A., Bauer M.P., Keller J.J., Mulder C.J.J., Kuijper E.J. Update of treatment algorithms for Clostridium diffi cile infection. Clin. Microbiol. Infect. 2018;24(5):452–462. DOI: 10.1016/j.cmi.2017.12.022
66. Peng Z., Ling L., Stratton C.W., Li C., Polage C.R., Wu B., Tang Y.W. Advances in the diagnosis and treatment of Clostridium diffi cile infections. Emerg. Microbes Infect. 2018;7(1):15. DOI: 10.1038/s41426-017-0019-4
67. Kassam Z., Lee C.H., Yuan Y., Hunt R.H. Fecal microbiota transplantation for Clostridium diffi cile infection: systematic review and meta-analysis. Am. J. Gastroenterol. 2013;108(4):500–8. DOI: 10.1038/ajg.2013.59
68. Liubakka A., Vaughn B.P. Clostridium diffi cile Infection and Fecal Microbiota Transplant. AACN Adv. Crit. Care. 2016;27(3):324–337. DOI: 10.4037/aacnacc2016703
69. Sartelli M., Di Bella S., McFarland L.V., Khanna S., FuruyaKanamori L., Abuzeid N., Abu-Zidan F.M., Ansaloni L., Augustin G., Bala M., Ben-Ishay O., Biffl W.L., Brecher S.M., CamachoOrtiz A., Caínzos M.A., Chan S., Cherry-Bukowiec J.R., Clanton J., Coccolini F., Cocuz M.E., Coimbra R., Cortese F., Cui Y., Czepiel J., Demetrashvili Z., Di Carlo I., Di Saverio S., Dumitru I.M., Eckmann C., Eiland E.H., Forrester J.D., Fraga G.P., Frossard J.L., Fry D.E., Galeiras R., Ghnnam W., Gomes C.A., Griffi ths E.A., Guirao X., Ahmed M.H., Herzog T., Kim J.I., Iqbal T., Isik A., Itani K.M.F., Labricciosa F.M., Lee Y.Y., Juang P., Karamarkovic A., Kim P.K., Kluger Y., Leppaniemi A., Lohsiriwat V., Machain G.M., Marwah S., Mazuski J.E., Metan G., Moore E.E., Moore F.A., Ordoñez C.A., Pagani L., Petrosillo N., Portela F., Rasa K., Rems M., Sakakushev B.E., Segovia-Lohse H., Sganga G., Shelat V.G., Spigaglia P., Tattevin P., Tranà C., Urbánek L., Ulrych J., Viale P., Baiocchi G.L., Catena F. 2019 update of the WSES guidelines for management of Clostridioides (Clostridium) diffi cile infection in surgical patients. World J. Emerg. Surg. 2019;14:8. DOI: 10.1186/s13017-019-0228-3
70. Khanna S., Shin A., Kelly C.P. Management of Clostridium diffi cile Infection in Infl ammatory Bowel Disease: Expert Review from the Clinical Practice Updates Committee of the AGA Institute. Clin. Gastroenterol. Hepatol. 2017;15(2):166–174. DOI: 10.1016/j.cgh.2016.10.024
Рецензия
Для цитирования:
Пургина Д.С., Лялина Л.В., Рассохин В.В. Инфекция Clos tri dium diffi cile и ее влияние на течение воспалительных заболеваний кишечника. Клиническая медицина. 2022;100(7-8):346-356. https://doi.org/10.30629/0023-2149-2022-100-7-8-346-356
For citation:
Purgina D.S., Lyalina L.V., Rassokhin V.V. Clostridium diffi cile infection and its eff ect on the course of infl ammatory bowel diseases. Clinical Medicine (Russian Journal). 2022;100(7-8):346-356. (In Russ.) https://doi.org/10.30629/0023-2149-2022-100-7-8-346-356
Просмотров:
537
Послать статью по эл. почте 